InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,266.95
(
0.28%
)
Post# of 94785
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

GorillaGorilla

Send PM Follow Ignore
Followers 21
Posts 2227
Boards Moderated 0
Alias Born 06/08/2009

GorillaGorilla

Re: None

Monday, 11/15/2010 9:19:57 AM

Monday, November 15, 2010 9:19:57 AM

Post# of 94785
BSPM - reiterates their guidance. Sounds like they changed terms of the Hep B drug - which resulted in lower orders, initially, but much improved cash flow. They claim that ordering improved end of Q3 and that continued into October.... interesting.

http://www.prnewswire.com/news-releases/biostar-pharmaceuticals-inc-reports-third-quarter-revenue-increase-of-297-to-202-million-108143374.html

rich
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up